Navigation Links
Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies

NEW YORK, November 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Agilent Technologies Inc. (NYSE: A), Mindray Medical International Ltd (NYSE: MR), C.R. Bard, Inc. (NYSE: BCR), Tornier N.V. (NASDAQ: TRNX), and Life Technologies Corp. (NASDAQ: LIFE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Agilent Technologies Inc. Research Report

On November 6, 2013, Agilent Technologies Inc. (Agilent) announced that the first near field communication (NFC) controller chipset developed by Shanghai Fudan Microelectronics, FM 1930 chip, has successfully achieved NFC Forum certification using Agilent RIDER T3111S RFID HF Conference Test System. According to the Company, Shanghai Integrated Circuit Technology & Industry Promotion Center (ICC) cooperated with TA Certification Lab and used NFC Forum-validated test equipment from Agilent to perform the NFC Forum digital certification. "We appreciate the professional technical support from Agilent, ICC and TA during this certification process," said Mr. Liu Yifei, Assistant General Manager of Shanghai Fudan Microelectronics Group. "Our certification demonstrates the compliance of our NFC controller chipsets and is a key milestone in our NFC strategy. We are the only vendor that can provide the NFC controller chip in mainland China. Having added NFC SE and NFC Tag chips, we now offer a complete NFC chip solution for our customers both here and abroad." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



Mindray Medical International Ltd Research Report

On November 4, 2013, Mindray Medical International Ltd (Mindray) announced its Q3 2013 results with net revenues of $296.3 million, up 15.3% YoY. Non-GAAP net income stood at $57.4 million, reflecting an increase of 14.5% YoY. "In the third quarter, we reported solid top-line growth. We are particularly happy with our continued strong sales performance in Western Europe. Certain key emerging markets also continued to do well, although demand in some countries remained soft due to external factors. In China, the recent weak market sentiment in the healthcare sector has caused some delays in purchasing activities in the third quarter. However, the industry fundamentals remain solid," said Mr. Li Xiting, Mindray's President and Co-CEO. "Reagent sales continued to climb this quarter, highlighting our success in ramping up this recurring IVD revenue." The Full Research Report on Mindray Medical International Ltd - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



C.R. Bard, Inc Research Report  

On October 30, 2013, C.R. Bard, Inc (Bard) reported that Kenneth Rosenfield, M.D., Section Head for Vascular Medicine and Intervention, Massachusetts General Hospital and LEVANT 2 Co-Primary Investigator, presented data related to the study design, demographics, and six-month follow-up results from the patients randomized in the LEVANT 2 Lutonix Drug-Coated Balloon (DCB) trial, at the Transcatheter Cardiovascular Therapies (TCT) conference in San Francisco, California. The Company informed that the follow-up results from randomized patients, treated with the Lutonix DCB demonstrated safety comparable to uncoated balloons (94.0% vs 94.1%) and superior primary patency (92.3% vs 82.7%, p=0.003) by Kaplan-Meier time-to-event analysis. According to Bard, interested parties may access the presentation slides at the Company website, which will be available for a limited time period. The Full Research Report on C.R. Bard, Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



Tornier N.V. Research Report

On November 5, 2013, Tornier N.V. (Tornier) released its Q3 FY 2013 financial results (period ended September 29, 2013) with revenues of $66.7 million, up 15.1% YoY. Q3 FY 2013 revenue of the Company's extremities product categories totaled $56.9 million, compared to $48.7 million in Q3 FY 2012. Tornier also reported that non-GAAP gross margins improved to 74.2% in Q3 FY 2013 from 73.4% in Q3 FY 2012. Dave Mowry, President and CEO of Tornier, said, "We delivered adjusted EBITDA within our guidance range despite the lower than expected revenue. This was driven by an improvement in non-GAAP gross margin and prudent management of operating expenses. We believe we have the infrastructure in place to support our double-digit constant currency revenue growth and enhanced operating leverage expectations." Tornier stated that for Q4 FY 2013 it expects constant currency revenue to range between $73 million to $77 million. The Full Research Report on Tornier N.V. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



Life Technologies Corp. Research Report

On November 5, 2013, Life Technologies Corp (Life Technologies) announced its Q3 2013 financial results. The Company's revenues increased 2.6% YoY to $935.1 million, driven by increases in the Company's Research Consumables and Bioproduction businesses, partially offset by declines in Genetic Analysis. GAAP net income was $180 million in Q3 2013, compared to net income of 65.6 million in Q3 2012. Meanwhile, non-GAAP EPS for the quarter increased 10.9% YoY to $1.02 in Q3 2013. "We are pleased with our mid-single digit revenue and double-digit non-GAAP EPS growth, which was driven by strength across our Research Consumables and Applied Sciences business groups, solid growth in Japan and emerging markets such as China, and continued stability in the U.S. and Europe," said Gregory T. Lucier, Chairman and CEO of Life Technologies. The Full Research Report on Life Technologies Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:




  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
2. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
3. Hologic to Host Investor Presentation at RSNA 2013
4. Thoratec Announces Presentations At Investor Conferences For November 2013
5. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
6. Vital Access Reports Live VWING Clinical Cases and SAVE Study Clinical Data Presentation at CiDA Conference
7. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
8. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
9. Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug Applications - Research Report on Alexion, Pacira, pSivida, Momenta and Impax
10. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
11. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Post Your Comments:
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
Breaking Medicine News(10 mins):